ENTRY       D11052                      Drug
NAME        Risankizumab (USAN/INN);
            Risankizumab (genetical recombination) (JAN);
            Risankizumab-rzaa;
            Skyrizi (TN)
PRODUCT     SKYRIZI (AbbVie)
FORMULA     C6476H9992N1720O2016S44
EXACT_MASS  145519.994
MOL_WEIGHT  145609.8041
SEQUENCE    (A chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DQTIHWMRQA PGQGLEWIGY IYPRDDSPKY
            NENFKGKVTI TADKSTSTAY MELSSLRSED TAVYYCAIPD RSGYAWFIYW GQGTLVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPEAAGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPG
            (B chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DQTIHWMRQA PGQGLEWIGY IYPRDDSPKY
            NENFKGKVTI TADKSTSTAY MELSSLRSED TAVYYCAIPD RSGYAWFIYW GQGTLVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPEAAGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
            QQGNVFSCSV MHEALHNHYT QKSLSLSPG
            (C chain)
            DIQMTQSPSS LSASVGDRVT ITCKASRDVA IAVAWYQQKP GKVPKLLIYW ASTRHTGVPS
            RFSGSGSRTD FTLTISSLQP EDVADYFCHQ YSSYPFTFGS GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (D chain)
            DIQMTQSPSS LSASVGDRVT ITCKASRDVA IAVAWYQQKP GKVPKLLIYW ASTRHTGVPS
            RFSGSGSRTD FTLTISSLQP EDVADYFCHQ YSSYPFTFGS GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: A22-A96, A147-A203, A223-C214, A229-B229, A232-B232, A264-A324, A370-A428, B22-B96, B147-B203, B223-D214, B264-B324, B370-B428, C23-C88, C134-C194, D23-D88, D134-D194)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC18
            Product: D11052<JP/US>
EFFICACY    Anti-inflammatory disease, Anti-IL-23 alpha antibody
  DISEASE   Plaque psoriasis [DS:H01656]
            Psoriatic arthritis [DS:H01507]
            Crohn's disease [DS:H00286]
  TYPE      Monoclonal antibody
TARGET      IL23A [HSA:51561] [KO:K05426]
  PATHWAY   hsa04060(51561)  Cytokine-cytokine receptor interaction
            hsa04630(51561)  JAK-STAT signaling pathway
            hsa04659(51561)  Th17 cell differentiation
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC18 Risankizumab
                  D11052  Risankizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Risankizumab
                 D11052  Risankizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D11052  Risankizumab (USAN/INN); Risankizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11052  Risankizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11052  Risankizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL23A
                 D11052  Risankizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11052
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11052
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11052
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11052
DBLINKS     CAS: 1612838-76-2
            PubChem: 363669765
///
